Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer.
Ai AmiokaTakayuki KadoyaSatoshi SueokaYoshie KobayashiShinsuke SasadaAkiko EmiNorio MasumotoMasaoki ItoKoh NakayamaMorihito OkadaPublished in: Breast cancer (Tokyo, Japan) (2021)
In ER-positive breast cancer, Wnt5a upregulates the CYP metabolic pathway and suppresses tamoxifen, paclitaxel, and cyclophosphamide resistance, all of the three, standard treatment methods for ER-positive breast cancer. Wnt5a is thus potentially involved in the poor prognosis of ER-positive breast cancer independently of the PI3K-AKT-mTOR signaling pathway.